The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Overview of the Health Innovation Award 2026: Promoting Sustainable Solutions in Healthcare
The Health Innovation Award continues its mission in 2026 by spotlighting data-driven projects that advance sustainability across Portugal’s health sector. Launched by Faculdade de Medicina da Universidade de Lisboa, Sanofi, and NTT DATA Portugal, it invites submissions through its dedicated plat...
Commitment to Health Strategies in Portugal: A Pathway Towards Sustainable Change
In advancing health strategies in Portugal, the Ordem dos Farmacêuticos met with Adalberto Campos Fernandes to urge the country to move from promising ideas to concrete implementation of the
European Health Resilience: Strengthening Preparedness Amidst Geopolitical Challenges
EFPIA and Vaccines Europe endorse the European Commission’s Communication titled “Reinforcing Global Health Resilience Amidst Geopolitical Change,” published on 13 May, as a constructive advancement in bolstering European Health Resilience within a fragmented global environment. The statement hig...